[HTML][HTML] Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated …
IP Naya, L Tombs, DA Lipson, C Compton - Advances in Therapy, 2018 - Springer
Introduction Assessing clinically important measures of disease progression is essential for
evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease …
evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease …
[HTML][HTML] Triple Therapy of Umeclidinium + Inhaled Corticosteroids/Long-Acting Beta2 Agonists for Patients with COPD: Pooled Results of Randomized Placebo …
TM Siler, E Kerwin, L Tombs, WA Fahy, I Naya - Pulmonary Therapy, 2016 - Springer
Introduction Data on triple therapy (long-acting muscarinic antagonist [LAMA]+ inhaled
corticosteroid/long-acting beta 2-agonist [ICS/LABA]) in symptomatic patients with chronic …
corticosteroid/long-acting beta 2-agonist [ICS/LABA]) in symptomatic patients with chronic …
[HTML][HTML] The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel …
AR Sousa, JH Riley, A Church, CQ Zhu… - NPJ Primary Care …, 2016 - nature.com
Benefits of triple therapy with a long-acting muscarinic antagonist (LAMA), added to inhaled
corticosteroid (ICS)/long-acting β 2-agonist (LABA), have been demonstrated. Limited data …
corticosteroid (ICS)/long-acting β 2-agonist (LABA), have been demonstrated. Limited data …
[HTML][HTML] Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled …
F Maltais, L Bjermer, EM Kerwin, PW Jones… - Respiratory …, 2019 - Springer
Background Prospective evidence is lacking regarding incremental benefits of long-acting
dual-versus mono-bronchodilation in improving symptoms and preventing short-term …
dual-versus mono-bronchodilation in improving symptoms and preventing short-term …
Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial
EM Kerwin, IH Boucot, CF Vogelmeier… - Therapeutic …, 2020 - journals.sagepub.com
Background: In chronic obstructive pulmonary disease (COPD), both the time needed for
patients to gain symptom improvement with long-acting bronchodilator therapy and whether …
patients to gain symptom improvement with long-acting bronchodilator therapy and whether …
Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
D Singh, MR Maleki-Yazdi, L Tombs… - … journal of chronic …, 2016 - Taylor & Francis
Background Minimizing the risk of disease progression and exacerbations is the key goal of
COPD management, as these are well-established indicators of poor COPD prognosis. We …
COPD management, as these are well-established indicators of poor COPD prognosis. We …
Comparative efficacy and safety of umeclidinium/vilanterol, umeclidinium and salmeterol in symptomatic maintenance-naïve and maintenance-treated chronic …
LH Bjermer, E Kerwin, F Maltais, P Jones… - B45. COPD …, 2019 - atsjournals.org
Rationale: In symptomatic, low exacerbation risk patients with chronic obstructive pulmonary
disease (COPD), long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist …
disease (COPD), long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist …
Treatment of COPD with long-acting bronchodilators: association between early and longer-term clinically important improvement
CF Vogelmeier, IP Naya, F Maltais… - … Journal of Chronic …, 2021 - Taylor & Francis
Introduction This post hoc analysis of the “Early MAXimization of bronchodilation for
improving COPD stability”(EMAX) trial investigated whether patients achieving early …
improving COPD stability”(EMAX) trial investigated whether patients achieving early …
Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data
MR Maleki-Yazdi, D Singh, A Anzueto, L Tombs, I Naya… - 2015 - Eur Respiratory Soc
Background: To investigate efficacy of umeclidinium/vilanterol (UMEC/VI) in preventing
clinically important deterioration (CID) in intent-to-treat (ITT) and maintenance-naïve (MN) …
clinically important deterioration (CID) in intent-to-treat (ITT) and maintenance-naïve (MN) …
[HTML][HTML] Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis
I Naya, L Tombs, DA Lipson, I Boucot, C Compton - Respiratory research, 2019 - Springer
Background Symptomatic patients with chronic obstructive pulmonary disease (COPD) and
low exacerbation risk still have disease instability, which can be improved with better …
low exacerbation risk still have disease instability, which can be improved with better …